Columbia University Irving Medical Center

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Medical Devices, Health, Genetics, Oncology, Genetic testing, Patient, Journal of the American Society of Nephrology, Kidney disease, Columbia University Irving Medical Center, Hematuria, Therapy, Medicare, Physician, AUC, Diabetes, NTRA, Journal, Society, Chronic kidney disease, Disease, Division, Medicine, Hypertension, Histology, Biopsy, Nephrology, CKD, Diagnosis, DNA, Pharmaceutical industry, Medical imaging, Dietary supplement

Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.

Key Points: 
  • Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.
  • In the RenaCARE study, 20.8% of CKD patients had a positive genetic finding.
  • Of those, 48.8% of patients received a new or reclassified diagnosis and 34% received information on disease subtype.
  • In the study, 35.5% of patients with positive results received a diagnosis that could make them eligible for available therapeutics.

POLARIS[AR] RECEIVES CLEARANCE FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR STELLAR KNEE

Retrieved on: 
Friday, November 3, 2023
Knee, FDA, Standard of care, Columbia University Irving Medical Center, Food, Surgeon, Orthopedic surgery, Elective surgery, University of California, Regulation of tobacco by the U.S. Food and Drug Administration, Software, Environment, Mixed reality, University, Columbia University, Algorithm, Augmented reality, Robotics, Associate, Medical device, Medical imaging

MIAMI, Nov. 3, 2023 /PRNewswire/ -- POLARISAR is pleased to announce today that their STELLAR Knee has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MIAMI, Nov. 3, 2023 /PRNewswire/ -- POLARISAR is pleased to announce today that their STELLAR Knee has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
  • STELLAR Knee is the first clearance for POLARISAR, a company focused on creating a new category in Mixed Reality surgical guidance.
  • The STELLAR Knee workflow is open and available to be utilized across all total knee replacement implant systems.
  • STELLAR Knee not only impacts the surgeon and the patient, but also empowers healthcare providers to change the standard of care."

YourBio Health Announces Expanded Regulatory Approval of its Virtually Painless Blood Collection Device

Retrieved on: 
Tuesday, October 31, 2023
Fertility, Columbia University Irving Medical Center, CE marking, CE, Health, Certification, Maintenance, Egg, Division, Phlebotomy, Women's health, GMED, Pain, Patient, Associate, Infertility, Medical device

MEDFORD, Mass., Oct. 31, 2023 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, today announced that it has received further regulatory approval for its TAP® Micro Select blood collection device with certification for CE Marking.

Key Points: 
  • MEDFORD, Mass., Oct. 31, 2023 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, today announced that it has received further regulatory approval for its TAP® Micro Select blood collection device with certification for CE Marking.
  • Harry Wilcox, Chief Executive Officer of YourBio Health, said, "With our patented Halo™ technology within the TAP® micro series of blood collection devices, YourBio Health is unique in offering virtually painless blood sample collection using a bladeless microneedle array.
  • Regulatory approval will enable our device's use with commercial blood collection tubes and allow use in kits that revolutionize blood testing in diagnostics and wellness."
  • The TAP® Micro Select blood collection device produces high-quality blood samples in high volumes, which can be processed at any central lab.

Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting

Retrieved on: 
Thursday, October 26, 2023
ASHG, Columbia University Irving Medical Center, Colab, Genomics, Anencephaly, DSM-IV codes, OGM, Genetics, Research, Society, Neurodevelopmental disorder, American Society of Human Genetics, Workflow, Pacific Northwest Diabetes Research Institute, Human genetics, Bone marrow, MECP2 duplication syndrome, Cancer, SAN, Medical device, Music

ASHG’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics and genetics research.

Key Points: 
  • ASHG’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics and genetics research.
  • Dr. Levy will present findings from the largest multisite study to date comparing OGM to classical cytogenetic methods for postnatal constitutional disorder research.
  • Dr. Stevenson will discuss his research using OGM for the analysis of neural tube defects.
  • In addition, 12 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

Retrieved on: 
Thursday, October 26, 2023
FAAD, Laboratory, FDA, Columbia University Irving Medical Center, FARMS, SciTech, University of Washington School of Medicine, Duke University, Therapy, SDP, MD, Publication, Retinoid, Duke University School of Medicine, Bone marrow, Fenretinide, Division, Clinical trial, Internal medicine, MAB, Emory University, Malignancy, Bexarotene, University, Immediate, Safety, Cancer, International Society, Patient, Toxicity, Fred Hutchinson Cancer Research Center, Lymphoma, Vaccine, Pharmaceutical industry, Research, Dermatology, Medicine

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.

Key Points: 
  • GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.
  • The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community.
  • The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D.
  • Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity."

COVID-19 Vaccine Protects Against the Corona Virus in Patients with Celiac Disease

Retrieved on: 
Tuesday, October 24, 2023
KSM, Research, Maccabi Healthcare Services, Coeliac disease, Columbia University Irving Medical Center, Pfizer–BioNTech COVID-19 vaccine, Vaccine, Innovation Center station, SARS-CoV-2, TEL, Head, Virus, Pfizer, COVID-19, Maccabi, Columbia University, Patient, Medical device, Pharmaceutical industry

TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ -- A retrospective study undertaken by Maccabi KSM Research in Israel has revealed that the Pfizer COVID-19 vaccine offers the same level of protection against the virus for patients with Celiac Disease as it does for those without this chronic condition.

Key Points: 
  • Throughout the pandemic, there were concerns surrounding whether individuals with Celiac Disease would generate an adequate immune response to COVID-19 vaccines.
  • These concerns stemmed from earlier research, which indicated reduced vaccine responsiveness among children with Celiac Disease to the hepatitis B vaccine.
  • Furthermore, the absence of data from COVID-19 vaccine clinical trials involving individuals with chronic conditions, including Celiac Disease, exacerbated these uncertainties.
  • There was also no significant difference between patients with controlled and uncontrolled Celiac Disease and in patients recently diagnosed with Celiac Disease.

The Lupus Research Alliance Walk with Us to Cure Lupus Takes Off at the Intrepid Museum

Retrieved on: 
Friday, October 20, 2023
Montefiore Medical Center, Walking, NFL, Intrepid Sea, Air & Space Museum, Columbia University Irving Medical Center, National Football League Foundation, Therapy, Government, Lupus Research Alliance, RPW, Hospital for Special Surgery, NYU Langone Health, Research, Walking day, Lupus, LRA, Air and Space Museum, Northwell Health, Disease, Atmosphere of Earth, GSK, Autoimmune disease, Columbia University, KPMG, Walkers, Hospital, Pharmaceutical industry, Aurinia, Genentech

NEW YORK, Oct. 20, 2023 /PRNewswire/ -- Thousands of supporters will join together Saturday, October 21 at the Intrepid Museum (formerly called the Intrepid Sea, Air and Space Museum) to celebrate the 20th Anniversary of the Lupus Research Alliance (LRA) 2023 New York City Walk with Us to Cure Lupus.

Key Points: 
  • NEW YORK, Oct. 20, 2023 /PRNewswire/ -- Thousands of supporters will join together Saturday, October 21 at the Intrepid Museum (formerly called the Intrepid Sea, Air and Space Museum) to celebrate the 20th Anniversary of the Lupus Research Alliance (LRA) 2023 New York City Walk with Us to Cure Lupus.
  • That number is still climbing as Walkers continue to fundraise for lupus research.
  • Because the LRA's Board of Directors covers all administrative and fundraising costs, 100 percent of these donations go directly to lupus research programs.
  • Joining the Walk with Us to Cure Lupus program to raise funds is just one way to contribute to the lupus cause.

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

Retrieved on: 
Tuesday, October 17, 2023
EGFR, APLS, Biomarker, Inflammation, Columbia University Irving Medical Center, Kidney failure, Society, Week, Columbia University, Recurrence, Disease, Kidney, ASN, Proteinuria, VALIANT, Rare, Adolescence, Poster, Glomerular filtration rate, American Society of Nephrology, Patient, Medical device, Pharmaceutical industry

The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.

Key Points: 
  • The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan.
  • Five (50%) patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline.
  • Excessive deposition of C3 breakdown products in the kidney leads to inflammation and damage of the kidney, often causing kidney failure.
  • Data from the Phase 2 DISCOVERY study investigating pegcetacoplan in patients with C3G in native kidneys was recently published in KI Reports .

Resilience Lab New Evidence-Informed Group Therapy Expands Mental Health Access and Allows for Insurance Coverage

Retrieved on: 
Thursday, October 5, 2023
COVID-19, Anxiety, Columbia University Irving Medical Center, Gold, Insurance, Columbia University, Private practice, Mental, EMR, Mental health, National Resilience Institute, Depression, Health care, Nursing

The country is facing a severe lack of mental health care providers, with more than 150 million people living in federally designated mental health professional shortage areas.

Key Points: 
  • The country is facing a severe lack of mental health care providers, with more than 150 million people living in federally designated mental health professional shortage areas.
  • Group therapy expands access to mental health services and reduces wait times for those seeking treatment.
  • Group therapy can increase the effectiveness of individual therapy or provide an alternative treatment for individuals who are struggling.
  • "Group therapy is a bonafide, standalone treatment that has a considerable benefit for those being treated for mental health disorders.

Lazurite® Names Dr. Christopher Proctor to its Medical Advisory Board

Retrieved on: 
Wednesday, October 4, 2023
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Columbia University, Pressure, Sports medicine, Surgeon, University, Shoulder, Arthroscopy Association of North America, California Collegiate League, Proctor, Injury, American Academy, Arthroscopy, Multimedia, Research, Elective surgery, Columbia University Irving Medical Center, Columbia, Medical Center, Joint, Orthopedic surgery, UCLA, Knee, Pharmaceutical industry, Dentistry

Medical device and technology company Lazurite® today announced that Christopher (Chris) S. Proctor, M.D., of De La Vina Surgicenter in Santa Barbara, California, has joined the company’s medical advisory board.

Key Points: 
  • Medical device and technology company Lazurite® today announced that Christopher (Chris) S. Proctor, M.D., of De La Vina Surgicenter in Santa Barbara, California, has joined the company’s medical advisory board.
  • “We are honored to have Dr. Proctor join our medical advisory board,” Lazurite CEO and cofounder Eugene Malinskiy said.
  • In addition to his accomplishments as a physician, he has also developed and patented devices, so he understands and appreciates innovation in medicine.”
    “I’m excited about joining Lazurite’s medical advisory board,” Proctor said.
  • Proctor has conducted extensive research on the structure, function and repair of joints and has published numerous articles and book chapters.